These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 21813056

  • 1. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA, Leardini G, Salaffi F, Intorcia M, Bellatreccia A, Dupont D, Beresniak A.
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
    Saraux A, Gossec L, Goupille P, Bregman B, Boccard E, Dupont D, Beresniak A.
    Rheumatology (Oxford); 2010 Apr; 49(4):733-40. PubMed ID: 20081224
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO.
    Clin Exp Rheumatol; 2018 Apr; 36(3):448-454. PubMed ID: 29303709
    [Abstract] [Full Text] [Related]

  • 5. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S, Benucci M, Favalli EG.
    Clin Exp Rheumatol; 2018 Apr; 36(3):479-485. PubMed ID: 29352843
    [Abstract] [Full Text] [Related]

  • 6. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.
    Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C.
    Clin Exp Rheumatol; 2013 Apr; 31(4):575-83. PubMed ID: 23711100
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.
    Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, Maclean R, Dupont D.
    Clin Rheumatol; 2009 Apr; 28(4):403-12. PubMed ID: 19089488
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 9. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.
    Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D.
    Int J Inflam; 2011 Sep; 2011():727634. PubMed ID: 21785694
    [Abstract] [Full Text] [Related]

  • 10. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L, Taylor M, Soonasra A, Bourret JA, Gerber RA.
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [Abstract] [Full Text] [Related]

  • 12. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S.
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [Abstract] [Full Text] [Related]

  • 13. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L, Baerwald C, Mennini FS, Rodríguez-Heredia JM, Bergman MJ, Choquette D, Herrmann KH, Attinà G, Nappi C, Merino SJ, Patel C, Mtibaa M, Foo J.
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [Abstract] [Full Text] [Related]

  • 14. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [Abstract] [Full Text] [Related]

  • 15. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 16. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.
    Sullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, Ringold S.
    J Med Econ; 2013 Aug 01; 16(3):391-6. PubMed ID: 23298329
    [Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A, Mariette X, Tubach F, Fautrel B, STRASS Study Group.
    Value Health; 2017 Apr 01; 20(4):577-585. PubMed ID: 28407999
    [Abstract] [Full Text] [Related]

  • 18. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.
    J Manag Care Spec Pharm; 2015 Apr 01; 21(4):318-29. PubMed ID: 25803765
    [Abstract] [Full Text] [Related]

  • 19. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y, Trivedi D, Maclean R, Rosenblatt L.
    J Med Econ; 2010 Mar 01; 13(1):33-41. PubMed ID: 20001596
    [Abstract] [Full Text] [Related]

  • 20. Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy.
    Gaultney J, Benucci M, Iannazzo S, Nappi C, Sion K, Sabater FJ.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun 01; 16(3):409-17. PubMed ID: 26495961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.